Bevacizumab - Diabetic macular oedema
You are here : Home > Formulary Search > Bevacizumab - Diabetic macular oedema
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Status 1
Non Formulary
Formulations :
- Intravitreal injection
Formulary Status :
Associated Icons :
Restrictions / Comments :
Important
Avastin is not supported for use in Diabetic Macular Oedema
Documentation
PAD Profile
ChemicalSubstance :
Bevacizumab
Indication :
Diabetic macular oedema
Group Name :
Keywords :
DMO
Brand Names Include :
Avastin
Important Information :
Latest Additions Date From :
03 Dec 2025
Latest Additions Date To :
31 Dec 2025
Guidelines :
Supporting Documents :
1
Committee Recommendations (1)
The Surrey Heartlands Integrated Care System Area Prescribing Committee have considered implementation of the NHS England Commissioning Guidance for Diabetic Macular Oedema (DMO) and a NON-FORMULARY traffic light status was agreed for Bevacizumab (Avastin).
Other Indications
Below are listed other indications that Bevacizumab is used to treat.
Other Drugs
Below are listed other drugs that are used to treat Diabetic macular oedema.